Full Press Release Details
Thiel JK, Cho E, Caggiano AO, et al. CT1812 preserves neurons and decreases levels of neurodegeneration biomarker NfL in disease-relevant neuronal model . Poster presented at Keystone 2025 ; Whistler, BC, Canada
CGTX Positive Sentiment
CT1812 preserves neurons and decreases levels of neurodegeneration biomarker NfL in disease-relevant neuronal model
Key Takeaway: CT1812 demonstrated the ability to preserve neurons and reduce levels of the neurodegeneration biomarker NfL in a relevant neuronal model. This research was presented at the Keystone 2025 conference in Whistler, BC, Canada, highlighting its potential significance in neurodegenerative disease treatment.
Price reaction · baseline $0.316 (2025-06-11T14:42:00.000Z) · hit during market hours · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+0.4%
Market Sentiment Analysis
POSITIVE FACTORS
- CT1812 shows promise in preserving neurons.
- Reduction in neurodegeneration biomarker NfL indicates potential efficacy.
- Research presented at a notable conference enhances visibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Frequently Asked Questions
What is CT1812?
CT1812 is a compound being studied for its potential to preserve neurons.
What biomarker does CT1812 affect?
CT1812 decreases levels of the neurodegeneration biomarker NfL.
Where was the research on CT1812 presented?
The research was presented at the Keystone 2025 conference in Whistler, BC.
What does the reduction of NfL indicate?
A reduction in NfL suggests potential efficacy in treating neurodegeneration.